The Molecular Glue Landscape

Monovalent degraders and molecular glues have received increasing amounts of attention and investment over the past few years, with an increasing number of them entering the clinic (three in 2021 and three more in 2022). With more companies entering the space there is a drive for collaboration in order to facilitate the development of assets from discovery to commercialisation.

With the current focus on their activity and potential (and in partnership with the Molecular Glue Drug Development Summit) our Beacon TPD team have created an infographic of the landscape so far.